2022
Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response
Liu S, Iorgulescu J, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity 2022, 55: 1940-1952.e5. PMID: 36223726, PMCID: PMC9745674, DOI: 10.1016/j.immuni.2022.09.002.Peer-Reviewed Original ResearchConceptsImmune responseTCR repertoireAntigen-specific immune responsesCell receptorDistinct TCR repertoireAdaptive immune responsesLymphoid germinal centersRenal cell carcinomaHeterogeneous immune responseCell carcinomaImmune cellsCell clonotypesT cellsImmune nichesAdjacent tumorGerminal centersMelanoma specimensCell responsesMouse spleenDistinct gene expressionGene expressionReceptorsCharacteristic locationCell typesCellsTranscriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.
Denize T, Hou Y, Pignon J, Walton E, West D, Freeman G, Braun D, Wu C, Gupta S, Motzer R, Atkins M, McDermott D, Choueiri T, Shukla S, Signoretti S. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research 2022, 28: 4045-4055. PMID: 35802667, PMCID: PMC9481706, DOI: 10.1158/1078-0432.ccr-22-0923.Peer-Reviewed Original ResearchMeSH KeywordsB7-H1 AntigenBiomarkers, TumorCarcinoma, Renal CellHumansKidney NeoplasmsNivolumabTranscriptomeConceptsTC PD-L1 expressionClear cell renal cell carcinomaPD-L1 expressionMetastatic clear cell renal cell carcinomaCell renal cell carcinomaRenal cell carcinomaProliferation-related pathwaysCell proliferation-related pathwaysClinical outcomesTumor cellsCell carcinomaTumor cell PD-L1 expressionAnti-PD-1 monotherapyPD-L1 positive tumorsHigher objective response rateLonger progression-free survivalTumor-infiltrating immune cellsTC PD-L1Objective response ratePD-L1 statusProgression-free survivalT-cell activation signaturesCheckMate 025 trialNivolumab monotherapyPD-L1
2016
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
Braun D, Burke K, Van Allen E. Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clinical Cancer Research 2016, 22: 5642-5650. PMID: 27698000, PMCID: PMC5135569, DOI: 10.1158/1078-0432.ccr-16-0066.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDrug Resistance, NeoplasmGenomicsHumansImmunotherapyMutationNeoplasmsTranscriptomeConceptsSubset of patientsCheckpoint blockadeSuch therapyImmune checkpoint blockadeImmune-based therapiesNumber of patientsLow intratumoral heterogeneityDurable responsesImmune checkpointsAdvanced cancerLoss of PTENNeoantigen loadPoint of careCertain patientsMechanisms of resistanceResistant tumorsPatientsTherapyTumor progressionImmunotherapyAppropriate functional studiesIntratumoral heterogeneityLimited responseBlockadePositive correlates